Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Business Wire (Mon, 2-Feb 7:00 AM ET)
Vyome Holdings Highlights VT-1953 Market Potential Analysis
TipRanks (Wed, 28-Jan 9:30 AM ET)
Market Chameleon (Tue, 27-Jan 4:52 AM ET)
Independent Analysis Sees Vyome’s VT-1953 Asset Value Approaching $1 Billion After Phase 3 Study
Market Chameleon (Tue, 27-Jan 3:20 AM ET)
Business Wire (Tue, 27-Jan 8:00 AM ET)
Business Wire (Mon, 8-Dec 8:00 AM ET)
Business Wire (Tue, 25-Nov 7:00 AM ET)
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Business Wire (Tue, 18-Nov 7:00 AM ET)
Vyome Holdings Announces Results of Annual Shareholder Meeting
Business Wire (Tue, 4-Nov 9:04 AM ET)
Vyome’s AI Acquisition Signals Strategic Shift Toward Digital Inflammation Therapies
Market Chameleon (Mon, 29-Sep 3:38 AM ET)
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.
Vyome Holdings trades on the NASDAQ stock market under the symbol HIND.
As of February 2, 2026, HIND stock price climbed to $2.04 with 353,467 million shares trading.
HIND has a beta of 1.72, meaning it tends to be more sensitive to market movements. HIND has a correlation of 0.03 to the broad based SPY ETF.
HIND has a market cap of $11.51 million. This is considered a Sub-Micro Cap stock.
HIND support price is $1.76 and resistance is $2.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HIND shares will trade within this expected range on the day.
